Get started
Author

Yan Moore

Treatment of Organ Confined Prostate Cancer with Third Generation Cryosurgery: Preliminary Multicenter Experience
2003 · KEN-RYU HAN, JEFF K. COHEN, et al. · The Journal of Urology · 205
Pilot Experience With Real-time Ultrasound Guided Percutaneous Renal Mass Cryoablation
2004 · MATTHEW J. BASSIGNANI, YAN MOORE, et al. · The Journal of Urology · 63
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study
2021 · Zev A. Wainberg, Tanios Bekaii-Saab, et al. · European Journal of Cancer · 58
PDF
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
2020 · Jasgit C. Sachdev, Pamela Munster, et al. · Breast Cancer Research and Treatment · 47
PDF
First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.
2021 · Timothy A. Yap, Ecaterina Elena Dumbrava, et al. · Journal of Clinical Oncology · 22
RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer
2022 · Luis Paz‐Ares, David R. Spigel, et al. · Cancer · 19
Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC).
2018 · Sarel Halachmi, Ilan Leibovitch, et al. · Journal of Clinical Oncology · 16
A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I).
2023 · Ildefonso I Rodriguez-Rivera, Ting-Hui Wu, et al. · Journal of Clinical Oncology · 12
PDF
NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
2020 · Zev A. Wainberg, Tanios S. Bekaii-Saab, et al. · Journal of Clinical Oncology · 10
Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65.
2014 · Roberto Bordonaro, Alberto F. Sobrero, et al. · Journal of Clinical Oncology · 8
RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase.
2019 · Luis G. Paz-Ares, David R. Spigel, et al. · Journal of Clinical Oncology · 5
RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
2020 · Luis G. Paz-Ares, David R. Spigel, et al. · Journal of Clinical Oncology · 4
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
2020 · David R. Spigel, Luis G. Paz-Ares, et al. · Journal of Clinical Oncology · 1
Abstract B14: CA 19-9 levels in patients with metastatic pancreatic adenocarcinoma receiving first-line therapy with liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NAPOX)
2019 · Farshid Dayyani, Patrick M. Boland, et al. · Cancer Research · 1
TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (BM)
2019 · Carey Anders, Pamela Munster, et al. · Neuro-Oncology Advances · 1
Abstract CT048: Phase I expansion study of irinotecan liposome injection (nal-IRI) in patients with metastatic breast cancer (mBC)
2019 · Jasgit Sachdev, Pamela Munster, et al. · Cancer Research · 1
Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.
2014 · Julien Taïeb, Roberto Bordonaro, et al. · Journal of Clinical Oncology · 1
Effect of MYC-targeting programmable epigenetic mRNA therapeutics on TME and immunotherapy responses.
2023 · Yan Moore, William Senapedis, et al. · Journal of Clinical Oncology
Abstract CT048: Phase I expansion study of irinotecan liposome injection (nal-IRI) in patients with metastatic breast cancer (mBC)
2019 · Jasgit Sachdev, Pamela Munster, et al. · Clinical Trials
PS01.69: Indirect Naive Comparison of ALK Inhibitors for ALK+ Non–Small Cell Lung Cancer (NSCLC) Post–Crizotinib Failure
2016 · Karen L. Reckamp, Joice Huang, et al. · Journal of Thoracic Oncology
PDF
Ziv-aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Third interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies).
2014 · Roberto Bordonaro, Alberto F. Sobrero, et al. · Journal of Clinical Oncology
Works count: 21
Citation count: 474
H-index: 9
I10-index: 9
Year
Topic
Type